Table 3.
Biochemical measurements.
| Biochemical variables | Reference intervals* | Lovastatin group | Minocycline group | ||||
|---|---|---|---|---|---|---|---|
| Baseline (n =11) | 8 weeks (n = 10) | 20 weeks (n = 11) | Baseline (n = 11) | 8 weeks (n = 11) | 20 weeks (n = 10) | ||
| CK | ≤ 150 IU/L | 84.27 ± 27.24 | 92.5 ± 30.27 | 105.27 ± 49 | 64.18 ± 28.91 | 70.82 ± 26.78 | 67.90 ± 21.86 |
| Creatinine | 37–110 μm/L | 65.64 ± 8.97 | 64.8 ± 10.13 | 69.55 ± 7.98 | 58.09 ± 14.85 | 58.73 ± 15.26 | 60.20 ± 16.27 |
| Lipid profile | |||||||
| TC | 3.2–5.48 mmol/L | 3.58 ± 0.74 | 2.83 ± 0.61 | 2.92 ± 0.55 | 3.71 ± 0.59 | 3.61 ± 0.82 | 2.92 ± 0.48† |
| HDL-C | 0.69–1.81 mmol/L | 1.01 ± 0.16 | 1.06 ± 0.18 | 1.07 ± 0.22 | 1.02 ± 0.19 | 1.04 ± 0.24 | 1.08 ± 0.31 |
| Non-HDL-C | 2.57 ± 0.77 | 1.77 ± 0.68 | 1.85 ± 0.68 | 2.69 ± 0.69 | 2.57 ± 0.89 | 1.85 ± 0.64† | |
| Apo B | 0.6–1.6 g/L | 0.77 ± 0.2 | 0.59 ± 0.17 | 0.63 ± 0.17 | 0.82 ± 0.23 | 0.78 ± 0.24 | 0.66 ± 0.19† |
| Liver profile | |||||||
| ALP | 35–485 IU/L | 97.91 ± 74.44 | 96.9 ± 73.04 | 97 ± 67.96 | 119 ± 94 | 125.6 ± 103.2 | 127.2 ± 94.9 |
| ALT | ≤ 55 IU/L | 26 ± 14.46 | 28.2 ± 14.53 | 26.73 ± 11.52 | 23.91 ± 17.52 | 31.09 ± 25.35 | 71.8 ± 125.4† |
| Bilirubin | 2.8–17 μm/L | 12.42 ± 8.59 | 13.78 ± 7.25 | 15.2 ± 14.19 | 8.89 ± 4.92 | 9.15 ± 5.66 | 11.65 ± 11.51 |
Data are presented as mean ± SD. CK, creatine kinase; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; Apo B, apolipoprotein B; ALP, alkaline phosphatase; ALT, alanine aminotransferase.
*
Reference intervals are in accordance with Roche Diagnostics® technical sheets.
†
p ≤ 0.01.